Porton Pharma Solutions Ltd. (SHE:300363)
China · Delayed Price · Currency is CNY 21.77
+0.22 (1.02%)
Apr 8, 2026, 3:04 PM CST
Porton Pharma Solutions Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,420 | 2,989 | 3,658 | 7,008 | 3,074 |
Other Revenue | - | 23.11 | 9.44 | 26.99 | 31.17 |
| 3,420 | 3,012 | 3,667 | 7,035 | 3,105 | |
Revenue Growth (YoY) | 13.54% | -17.87% | -47.87% | 126.55% | 49.87% |
Cost of Revenue | 2,396 | 2,309 | 2,230 | 3,398 | 1,843 |
Gross Profit | 1,024 | 702.62 | 1,437 | 3,636 | 1,262 |
Selling, General & Admin | 559.38 | 557.81 | 693.17 | 807.66 | 386.63 |
Research & Development | 267.58 | 338.49 | 452.23 | 519.51 | 262.02 |
Other Operating Expenses | -14.14 | 10.05 | 35.09 | 58.54 | 14.06 |
Operating Expenses | 812.82 | 926.63 | 1,145 | 1,419 | 706.17 |
Operating Income | 211.03 | -224 | 291.88 | 2,218 | 555.88 |
Interest Expense | - | -62.06 | -44.15 | -27.73 | -21.7 |
Interest & Investment Income | - | 24.08 | 57.88 | 22.83 | 14.31 |
Currency Exchange Gain (Loss) | - | 10.11 | -20.01 | 50.25 | 10.79 |
Other Non Operating Income (Expenses) | -97.19 | -1.64 | -2.53 | -6.73 | -1.5 |
EBT Excluding Unusual Items | 113.84 | -253.5 | 283.07 | 2,256 | 557.77 |
Impairment of Goodwill | - | - | -40.64 | - | - |
Gain (Loss) on Sale of Investments | 6.52 | -49.24 | -1.63 | -8.18 | -6.79 |
Gain (Loss) on Sale of Assets | -1.17 | -0.77 | 0.54 | 0.1 | -3.21 |
Asset Writedown | -36.52 | -92.57 | -17.49 | -18.63 | -16.22 |
Other Unusual Items | - | 22.04 | 22.71 | 16.28 | 17.28 |
Pretax Income | 82.68 | -374.05 | 246.56 | 2,246 | 548.83 |
Income Tax Expense | 52.29 | -8.06 | 71.05 | 309.38 | 73.24 |
Earnings From Continuing Operations | 30.39 | -365.99 | 175.52 | 1,936 | 475.59 |
Minority Interest in Earnings | 65.95 | 78.24 | 91.34 | 68.99 | 48.33 |
Net Income | 96.34 | -287.75 | 266.86 | 2,005 | 523.92 |
Net Income to Common | 96.34 | -287.75 | 266.86 | 2,005 | 523.92 |
Net Income Growth | - | - | -86.69% | 282.78% | 61.49% |
Shares Outstanding (Basic) | 535 | 543 | 545 | 542 | 540 |
Shares Outstanding (Diluted) | 535 | 543 | 545 | 543 | 540 |
Shares Change (YoY) | -1.42% | -0.31% | 0.21% | 0.62% | -0.11% |
EPS (Basic) | 0.18 | -0.53 | 0.49 | 3.70 | 0.97 |
EPS (Diluted) | 0.18 | -0.53 | 0.49 | 3.69 | 0.97 |
EPS Growth | - | - | -86.72% | 280.41% | 61.67% |
Free Cash Flow | 464.45 | -85.06 | -500.81 | 1,391 | -296.8 |
Free Cash Flow Per Share | 0.87 | -0.16 | -0.92 | 2.56 | -0.55 |
Dividend Per Share | - | - | 0.487 | 1.106 | 0.193 |
Dividend Growth | - | - | -55.97% | 473.06% | 59.50% |
Gross Margin | 29.94% | 23.33% | 39.19% | 51.69% | 40.64% |
Operating Margin | 6.17% | -7.44% | 7.96% | 31.52% | 17.90% |
Profit Margin | 2.82% | -9.55% | 7.28% | 28.51% | 16.87% |
Free Cash Flow Margin | 13.58% | -2.82% | -13.66% | 19.78% | -9.56% |
EBITDA | 570.05 | 95.9 | 580.68 | 2,452 | 719.86 |
EBITDA Margin | 16.67% | 3.18% | 15.83% | 34.86% | 23.18% |
D&A For EBITDA | 359.02 | 319.9 | 288.8 | 234.54 | 163.98 |
EBIT | 211.03 | -224 | 291.88 | 2,218 | 555.88 |
EBIT Margin | 6.17% | -7.44% | 7.96% | 31.52% | 17.90% |
Effective Tax Rate | 63.24% | - | 28.81% | 13.78% | 13.35% |
Revenue as Reported | - | 3,012 | 3,667 | 7,035 | 3,105 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.